Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine.
Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine.
复制标题
DOI：
10.12688/f1000research.111300.1
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
仅使用羟基脲（HU）就有可能预防三分之一因镰状细胞病（SCD）导致的死亡，以及几乎所有由镰状细胞病引发的残疾。然而，在坦桑尼亚，SPARCO - 坦桑尼亚镰状细胞队列中每六名登记在册的镰状细胞病患者中只有一人使用羟基脲。我们开展研究以了解影响坦桑尼亚羟基脲使用情况的因素，结果发现，羟基脲使用率低的原因包括：羟基脲被归类为抗癌药物，只有血液科医生才可开具该药处方，羟基脲仅在国家医院和专科医院限量处方，使用国家健康保险基金（NHIF）计划获取羟基脲需要特殊许可，以及羟基脲进口受限且坦桑尼亚本地无生产，限制了这种重要药物的可及性。因此，基于此简述，政府应允许在地区医院层面开具羟基脲处方，应允许所有至少拥有医学学士学位的临床医生开具羟基脲处方，并且应简化通过国家健康保险基金获取羟基脲的流程。
Hydroxyurea (HU) alone has the potential to prevent one out of every three deaths due to sickle cell disease (SCD) and almost all forms of disabilities caused by SCD. However, in Tanzania, only one out of every six registered SCD patients in the SPARCO-Tanzania Sickle Cell Cohort use HU. We conducted studies to understand factors influencing utilization of HU in Tanzania and discovered that among the reason for low utilization of HU include HU is classified as anticancer medication, only hematologists are supposed to prescribe HU, limited HU prescription to only National and Specialized hospitals, a special permit is required to access HU using National Health Insurance Fund (NHIF) scheme and limited importation and absence of local manufacturing of HU limit availability of this important drug in Tanzania. Therefore, with this brief, the government should allow prescription of HU to the district hospitals level, should allow all clinicians with a minimum of a Bachelor of Medicine to prescribe HU, and accessibility of HU through NHIF should be friendly.